Bullish
Pfizer's stock rises 1.6% to $27.30 amid positive vaccine news and pipeline progress.
Pfizer's stock price increased by 1.6% to $27.30, driven by the European Medicines Agency's validation of its Lyme disease vaccine application and advancements in its obesity drug pipeline. The broader healthcare sector's strength also contributed to the positive momentum.
Key points
- EMA validates Pfizer's Lyme disease vaccine application, advancing regulatory review.
- Pfizer completes Phase 1 study of experimental obesity drug PF-08653944, diversifying its pipeline.
- Healthcare sector strength supports Pfizer's stock performance.
- Analysts maintain a 'Hold' rating with an average price target of $28.28, citing patent-expiration risks.
Sources
AI-generated from public news sources. Not financial advice.
